Opaleye Cuts 28,315 Eton Shares on July 14: Market‑Move or Tactical Exit?
Opaleye’s July 14 sale of 28,315 Eton Pharma shares taps a price surge, signaling a tactical exit while keeping a residual stake for future upside.
3 minutes to read
ETON PHARMACEUTICALS INC
Opaleye’s July 14 Sale of Eton Shares Boosts Pipeline Growth, Not Panic
Opaleye’s July share sale shows strategic rebalancing, not a warning, for Eton Pharmaceuticals – whose eye and skin biologics move from Phase II to fast‑track Phase III, backed by strong safety data and global IND approvals.
4 minutes to read
CEO Insider Sales at Eton Pharma: Market Impact and Investor Insight
CEO insider sales at Eton Pharmaceuticals signal a tactical liquidity move, not a crisis, but investors should watch earnings and pipeline updates closely.
4 minutes to read
Insider Buying Signals at Eton Pharma: Riedel’s Bet Signals Future Upside
Insider buying at Eton Pharmaceuticals signals confidence in its low‑priced, high‑potential pipeline, offering investors a contrarian entry point amid a 12‑week decline.
4 minutes to read